Tenofovir may reduce risk of liver cancer in patients with HBV infection
the ONA take:
A new study published online ahead of print in the journal Cancer has shown that long-term therapy with tenofovir disoproxil fumarate (TDF) was associated with a decreased incidence of hepatocellular carcinoma among patients with chronic hepatitis B virus (HBV) infection without cirrhosis.
According to the American Cancer Society, there will be nearly 36,000 new cases of liver cancer diagnosed in the 2015 and about 24,550 people will die from the disease.
For the study, researchers analyzed data from the pivotal TDF registration studies that followed patients for 384 weeks. Of the 634 patients included for analysis, 152 had cirrhosis and 482 did not. During the study period, 14 patients developed hepatocellular carcinoma.
Results showed that the incidence of hepatocellular carcinoma was significantly lower than predicted among patients without cirrhosis.
TDF is an oral antiviral medication used to treat HIV infection in combination with other drugs and chronic HBV infection.
Long-term therapy with tenofovir was associated with a decreased incidence of HCC among patients with chronic HBV infection without cirrhosis.
- Physical Activity Improves Outcomes for Patients with Breast Cancer and Survivors
- Behavior Pain Assessment Tool Measures Pain In Patients Who Cannot Communicate Verbally
- Whole Genome Sequencing Reveals that 12% of Childhood Cancer Survivors Have Mutations in Genes that Increase Cancer Risk
- Increased 5-Year Survival Rate Seen in NSCLC Subset Treated With Nivolumab
- Novel Test For Multiple Myeloma Uses Microchip, Conventional Blood Sample
- Exercise, Psychological Interventions Better for Cancer Fatigue Than Medications
- ASCO Issues Global Guidance for HPV Vaccination for Cervical Cancer Prevention
- Discharge Events Improved With Standardized Inpatient Palliative Care Consultation
- Little Opposition to Early Palliative Care for Symptom Management in Pediatric Oncology
- Updated ASTRO Guideline Bolsters Safety, Efficacy of Palliative RT for Bone Metastases
- Thyroid Cancer Incidence Increasing Among Younger, Hispanic, African American Populations
- JAK1, JAK2 Inhibition Improves Outcomes in Myeloproliferative Neoplasms, But More Is Needed
- Recommendations Against Contralateral Prophylactic Mastectomy Not Tied to Patient Satisfaction
- Self-efficacy Level Predictive of Likelihood to Follow Through With Colorectal Cancer Screening
- Chronic Myeloproliferative Neoplasms Treatment (Fact Sheet)
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|